跳至主要内容
临床试验/NCT01132495
NCT01132495已完成不适用

Fractional Flow Reserve-Guided Percutaneous Coronary Intervention Plus Optimal Medical Treatment Versus Optimal Medical Treatment Alone in Patients With Stable Coronary Artery Disease

Abbott Medical Devices57 个研究点 分布在 13 个国家目标入组 1,170 人开始时间: 2010年5月最近更新:
适应症
干预措施

试验速览

阶段
不适用
状态
已完成
入组人数
1,170
试验地点
57
主要终点
Major Adverse Cardiac Event Rate (MACE)

研究概览

简要总结

The overall purpose of the FAME II trial is to compare the clinical outcomes, safety and cost-effectiveness of FFR-guided PCI plus optimal medical treatment (OMT) versus OMT alone in patients with stable coronary artery disease.

详细描述

Prospective, multi-center, multi-national, multi-continental, randomized clinical trial.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Diagnostic
盲法
None

入排标准

年龄范围
21 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Patients with
  • stable angina or,
  • stabilized angina pectoris or,
  • atypical chest pain or no chest pain but with documented silent ischemia
  • at least one stenosis is present of at least 50% in one major native epicardial coronary artery and supplying viable myocardium
  • Eligible for PCI
  • Signed written informed consent

排除标准

  • Patients in whom the preferred treatment is CABG
  • Patients with left main coronary artery disease requiring revascularization
  • Patients with a recent STEMI or Non-STEMI
  • Contra-indication to dual antiplatelet therapy
  • LVEF < 30%
  • Severe LV hypertrophy
  • Planned need for concomitant cardiac surgery
  • Extremely tortuous or calcified coronary arteries precluding FFR measurements
  • A life expectancy of less than 2 years
  • Age under 21

研究组 & 干预措施

Cohort A: PCI plus OMT

Other

PCI plus optimal medical treatment

干预措施: Stenting plus OMT (Other)

Cohort A: OMT alone

Other

Optimal medical treatment alone

干预措施: OMT (Other)

Cohort B

Other

FFR > 0.80; treatment according to local practice

干预措施: Standard of care (Other)

结局指标

主要结局

Major Adverse Cardiac Event Rate (MACE)

时间窗: 24 Month

MACE: A composite of all cause death, documented MI, unplanned hospitalization leading to urgent revascularization.

次要结局

  • Overall MACE(3 years)

研究者

申办方类型
Industry
责任方
Sponsor

研究点 (57)

Loading locations...

相似试验